Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Oil and natural gas company Denbury Resources Inc. ( DNR - Analyst Report ) has raised its 2012 annual production guidance. The company expects total production for 2012 in the range of 69,775–74,775 barrels of oil equivalent per day (Boe/d).
The 1,150 Boe/d increment in production estimate was made following the closure of its purchase of Thompson Field in Fort Bend County, Texas. The raised guidance reflects average daily production of about 2,000 barrels of oil from the properties acquired, for the remainder of 2012. Denbury targets its total production in the upper half of the company's estimated range.
The acquisition of Thompson Field cost the company approximately $360 million prior to purchase price adjustments. Denbury proposes to fund the purchase with $213 million in cash (generated from its sale of non-core properties earlier in 2012) and borrowing under its revolving credit facility. The portion of the acquisition that was financed by the property sale did not generate any tax liability on it, thereby facilitating the company with a tax gain of $30 million in 2012.
The Thompson field in Fort Bend County produces 2,200 barrels of oil per day and holds potential conventional reserve capacity of around 17 million barrels of oil. The 8,454 acre oilfield, which produces oil from the Frio zone, is located 18 miles west of the Hastings field, and will be used to enhance oil recovery by pumping carbon dioxide.
The Thompson field, discovered in the early 1930s, was jointly owned and operated by Chevron Corporation ( CVX - Analyst Report ) and ExxonMobil Corporation ( XOM - Analyst Report ) from 1932 onwards. Later, both companies sold their stakes in separate transactions to a private buyer, who then sold it to Denbury in 1999 and 2003.
Denbury holds a Zacks #3 Rank, which translates to a Hold rating for a period of one to three months. For the long term, we maintain our Neutral recommendation.
Read the full Analyst Report on CVX
Read the full Analyst Report on DNR
Read the full Analyst Report on XOM